How much profit has Cosmo Pharmaceuticals made this year?
Cosmo Pharmaceuticals has made 123.69 M EUR this year.
Cosmo Pharmaceuticals Net Income 2024
Cosmo Pharmaceuticals Net Income
123.69 M EUR
Ticker
COPN.SW
ISIN
NL0011832936
WKN
A2AJ68
In 2024, Cosmo Pharmaceuticals's profit amounted to 123.69 M EUR, a 10,683.95% increase from the 1.15 M EUR profit recorded in the previous year.
The Cosmo Pharmaceuticals Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2029e | 271.43 |
| 2028e | 83.19 |
| 2027e | 79.42 |
| 2026e | 78.94 |
| 2025e | 91.04 |
| 2024e | 123.69 |
| 2023 | 1.15 |
| 2022 | 17.23 |
| 2021 | 21.67 |
| 2020 | -7.9 |
| 2019 | -24.42 |
| 2018 | -18.01 |
| 2017 | -32.45 |
| 2016 | 19.34 |
| 2015 | 248.19 |
| 2014 | 73.32 |
| 2013 | 68.73 |
| 2012 | 19.32 |
| 2011 | 7.6 |
| 2010 | 3.61 |
| 2009 | 4.05 |
| 2008 | 9.4 |
| 2007 | 0.12 |
| 2006 | -0.34 |
Cosmo Pharmaceuticals Revenue, EBIT, Net Income NL0011832936 · A2AJ68
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Cosmo Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cosmo Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cosmo Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Cosmo Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Cosmo Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Cosmo Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cosmo Pharmaceuticals’s growth potential.
Cosmo Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Cosmo Pharmaceuticals Revenue | Cosmo Pharmaceuticals EBIT | Cosmo Pharmaceuticals Net Income |
|---|---|---|---|
| 2029e | 556.57 M undefined | 0 undefined | 271.43 M undefined |
| 2028e | 248.71 M undefined | 110.83 M undefined | 83.19 M undefined |
| 2027e | 235.95 M undefined | 106.44 M undefined | 79.42 M undefined |
| 2026e | 256.7 M undefined | 107.54 M undefined | 78.94 M undefined |
| 2025e | 252.27 M undefined | 125.97 M undefined | 91.04 M undefined |
| 2024e | 269.85 M undefined | 165.57 M undefined | 123.69 M undefined |
| 2023 | 96.72 M undefined | 12.23 M undefined | 1.15 M undefined |
| 2022 | 102.09 M undefined | 28.06 M undefined | 17.23 M undefined |
| 2021 | 65.07 M undefined | 11.1 M undefined | 21.67 M undefined |
| 2020 | 60.95 M undefined | 2.91 M undefined | -7.9 M undefined |
| 2019 | 62.5 M undefined | -12.31 M undefined | -24.42 M undefined |
| 2018 | 65.62 M undefined | -16.62 M undefined | -18.01 M undefined |
| 2017 | 67.24 M undefined | -9.6 M undefined | -32.45 M undefined |
| 2016 | 67.66 M undefined | 24.63 M undefined | 19.34 M undefined |
| 2015 | 60.61 M undefined | -5.43 M undefined | 248.19 M undefined |
| 2014 | 79.59 M undefined | 22.21 M undefined | 73.32 M undefined |
| 2013 | 56.37 M undefined | 12.94 M undefined | 68.73 M undefined |
| 2012 | 59.54 M undefined | 26.46 M undefined | 19.32 M undefined |
| 2011 | 33.51 M undefined | 8.91 M undefined | 7.6 M undefined |
| 2010 | 32.05 M undefined | 4.8 M undefined | 3.61 M undefined |
| 2009 | 26.69 M undefined | 4.44 M undefined | 4.05 M undefined |
| 2008 | 34.17 M undefined | 11.18 M undefined | 9.4 M undefined |
| 2007 | 22.42 M undefined | -250,000 undefined | 120,000 undefined |
| 2006 | 20.09 M undefined | 1.44 M undefined | -340,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 20.09 M EUR | 1.44 M EUR | -340,000 EUR |
| 2007 | 22.42 M EUR | -250,000 EUR | 120,000 EUR |
| 2008 | 34.17 M EUR | 11.18 M EUR | 9.4 M EUR |
| 2009 | 26.69 M EUR | 4.44 M EUR | 4.05 M EUR |
| 2010 | 32.05 M EUR | 4.8 M EUR | 3.61 M EUR |
| 2011 | 33.51 M EUR | 8.91 M EUR | 7.6 M EUR |
| 2012 | 59.54 M EUR | 26.46 M EUR | 19.32 M EUR |
| 2013 | 56.37 M EUR | 12.94 M EUR | 68.73 M EUR |
| 2014 | 79.59 M EUR | 22.21 M EUR | 73.32 M EUR |
| 2015 | 60.61 M EUR | -5.43 M EUR | 248.19 M EUR |
| 2016 | 67.66 M EUR | 24.63 M EUR | 19.34 M EUR |
| 2017 | 67.24 M EUR | -9.6 M EUR | -32.45 M EUR |
| 2018 | 65.62 M EUR | -16.62 M EUR | -18.01 M EUR |
| 2019 | 62.5 M EUR | -12.31 M EUR | -24.42 M EUR |
| 2020 | 60.95 M EUR | 2.91 M EUR | -7.9 M EUR |
| 2021 | 65.07 M EUR | 11.1 M EUR | 21.67 M EUR |
| 2022 | 102.09 M EUR | 28.06 M EUR | 17.23 M EUR |
| 2023 | 96.72 M EUR | 12.23 M EUR | 1.15 M EUR |
| 2024e | 269.85 M EUR | 165.57 M EUR | 123.69 M EUR |
| 2025e | 252.27 M EUR | 125.97 M EUR | 91.04 M EUR |
| 2026e | 256.7 M EUR | 107.54 M EUR | 78.94 M EUR |
| 2027e | 235.95 M EUR | 106.44 M EUR | 79.42 M EUR |
| 2028e | 248.71 M EUR | 110.83 M EUR | 83.19 M EUR |
| 2029e | 556.57 M EUR | 0 EUR | 271.43 M EUR |
Cosmo Pharmaceuticals stock margins NL0011832936 · A2AJ68
The Cosmo Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cosmo Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cosmo Pharmaceuticals.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Cosmo Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Cosmo Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Cosmo Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Cosmo Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cosmo Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cosmo Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cosmo Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Cosmo Pharmaceuticals Margin History
| Cosmo Pharmaceuticals Gross margin | Cosmo Pharmaceuticals Profit margin | Cosmo Pharmaceuticals EBIT margin | Cosmo Pharmaceuticals Profit margin |
|---|---|---|---|
| 2029e | 59.33 % | 0 % | 48.77 % |
| 2028e | 59.33 % | 44.56 % | 33.45 % |
| 2027e | 59.33 % | 45.11 % | 33.66 % |
| 2026e | 59.33 % | 41.89 % | 30.75 % |
| 2025e | 59.33 % | 49.93 % | 36.09 % |
| 2024e | 59.33 % | 61.36 % | 45.84 % |
| 2023 | 59.33 % | 12.64 % | 1.19 % |
| 2022 | 60.34 % | 27.48 % | 16.87 % |
| 2021 | 49.32 % | 17.06 % | 33.3 % |
| 2020 | 54.69 % | 4.77 % | -12.96 % |
| 2019 | 59.91 % | -19.69 % | -39.07 % |
| 2018 | 66.38 % | -25.33 % | -27.44 % |
| 2017 | 67.3 % | -14.28 % | -48.25 % |
| 2016 | 70.66 % | 36.4 % | 28.58 % |
| 2015 | 66.82 % | -8.97 % | 409.51 % |
| 2014 | 72.94 % | 27.91 % | 92.12 % |
| 2013 | 66.01 % | 22.96 % | 121.93 % |
| 2012 | 72.69 % | 44.44 % | 32.45 % |
| 2011 | 56.76 % | 26.59 % | 22.68 % |
| 2010 | 55.29 % | 14.98 % | 11.26 % |
| 2009 | 52.12 % | 16.64 % | 15.17 % |
| 2008 | 61.37 % | 32.72 % | 27.51 % |
| 2007 | 72.03 % | -1.12 % | 0.54 % |
| 2006 | 72.67 % | 7.17 % | -1.69 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 72.67 % | 7.17 % | -1.69 % |
| 2007 | 72.03 % | -1.12 % | 0.54 % |
| 2008 | 61.37 % | 32.72 % | 27.51 % |
| 2009 | 52.12 % | 16.64 % | 15.17 % |
| 2010 | 55.29 % | 14.98 % | 11.26 % |
| 2011 | 56.76 % | 26.59 % | 22.68 % |
| 2012 | 72.69 % | 44.44 % | 32.45 % |
| 2013 | 66.01 % | 22.96 % | 121.93 % |
| 2014 | 72.94 % | 27.91 % | 92.12 % |
| 2015 | 66.82 % | -8.97 % | 409.51 % |
| 2016 | 70.66 % | 36.4 % | 28.58 % |
| 2017 | 67.3 % | -14.28 % | -48.25 % |
| 2018 | 66.38 % | -25.33 % | -27.44 % |
| 2019 | 59.91 % | -19.69 % | -39.07 % |
| 2020 | 54.69 % | 4.77 % | -12.96 % |
| 2021 | 49.32 % | 17.06 % | 33.3 % |
| 2022 | 60.34 % | 27.48 % | 16.87 % |
| 2023 | 59.33 % | 12.64 % | 1.19 % |
| 2024e | 59.33 % | 61.36 % | 45.84 % |
| 2025e | 59.33 % | 49.93 % | 36.09 % |
| 2026e | 59.33 % | 41.89 % | 30.75 % |
| 2027e | 59.33 % | 45.11 % | 33.66 % |
| 2028e | 59.33 % | 44.56 % | 33.45 % |
| 2029e | 59.33 % | 0 % | 48.77 % |
Cosmo Pharmaceuticals Aktienanalyse
What does Cosmo Pharmaceuticals do?
Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Cosmo Pharmaceuticals's Profit Margins
The profit margins of Cosmo Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cosmo Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Cosmo Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Cosmo Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Cosmo Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Cosmo Pharmaceuticals stock
How has the profit developed compared to last year?
The profit has increased by 10,683.95% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Cosmo Pharmaceuticals publish its earnings?
Cosmo Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Cosmo Pharmaceuticals?
The profits of Cosmo Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Cosmo Pharmaceuticals?
You can learn more about the earnings of Cosmo Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Cosmo Pharmaceuticals pay?
Over the past 12 months, Cosmo Pharmaceuticals paid a dividend of 1.05 EUR . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Cosmo Pharmaceuticals is expected to pay a dividend of 1.05 EUR.
What is the dividend yield of Cosmo Pharmaceuticals?
The current dividend yield of Cosmo Pharmaceuticals is 1.29 %.
When does Cosmo Pharmaceuticals pay dividends?
Cosmo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, June, June, August.
How secure is the dividend of Cosmo Pharmaceuticals?
Cosmo Pharmaceuticals paid dividends every year for the past 8 years.
What is the dividend of Cosmo Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 1.29 %.
In which sector is Cosmo Pharmaceuticals located?
Cosmo Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cosmo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cosmo Pharmaceuticals from 7/12/2024 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.
When did Cosmo Pharmaceuticals pay the last dividend?
The last dividend was paid out on 7/12/2024.
What was the dividend of Cosmo Pharmaceuticals in the year 2023?
In the year 2023, Cosmo Pharmaceuticals distributed 0.95 EUR as dividends.
In which currency does Cosmo Pharmaceuticals pay out the dividend?
The dividends of Cosmo Pharmaceuticals are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cosmo Pharmaceuticals
Our stock analysis for Cosmo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Cosmo Pharmaceuticals Revenue
- Cosmo Pharmaceuticals Net Income
- Cosmo Pharmaceuticals P/E
- Cosmo Pharmaceuticals P/S
- Cosmo Pharmaceuticals EBIT
- Cosmo Pharmaceuticals Dividend
- Cosmo Pharmaceuticals Stocks
- Cosmo Pharmaceuticals Market capitalization
- Cosmo Pharmaceuticals Debt
- Cosmo Pharmaceuticals Liabilities
- Cosmo Pharmaceuticals Equity
- Cosmo Pharmaceuticals AAQS
- Cosmo Pharmaceuticals Employees
- Cosmo Pharmaceuticals ROE
- Cosmo Pharmaceuticals ROA
- Cosmo Pharmaceuticals ROCE
